Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose M Pacheco

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Frontiers in Oncology|May 1, 2020
Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With <i>EGFR</i>-Mutant Non-small Cell Lung CancerTejas Patil, Jose M Pacheco, Anastasios Dimou, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung CancerJacob Langston, Tejas Patil, D Ross Camidge, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2019
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung CancerJose M Pacheco, Dexiang Gao, Derek Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS</i>-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS MetastasesMarcelo V Negrao, Alexander I Spira, Rebecca S Heist, et al.
Clinical Lung Cancer|December 21, 2019
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung CancerTejas Patil, Rao Mushtaq, Sydney Marsh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2017
Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung CancerTyler P Robin, D Ross Camidge, Kelly Stuhr, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 1, 2021
Mutational Profile Evaluates Response and Survival to First-Line Chemotherapy in Lung CancerYayi He, Lele Song, Hao Wang, et al.
The Lancet. Oncology|March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trialEgbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.
The New England Journal of Medicine|September 17, 2021
Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung CancerBob T Li, Egbert F Smit, Yasushi Goto, et al.
The New England Journal of Medicine|June 3, 2022
Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> MutationPasi A Jänne, Gregory J Riely, Shirish M Gadgeel, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|May 1, 2020
Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With <i>EGFR</i>-Mutant Non-small Cell Lung CancerTejas Patil, Jose M Pacheco, Anastasios Dimou, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung CancerJacob Langston, Tejas Patil, D Ross Camidge, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2019
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung CancerJose M Pacheco, Dexiang Gao, Derek Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS</i>-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS MetastasesMarcelo V Negrao, Alexander I Spira, Rebecca S Heist, et al.
Clinical Lung Cancer|December 21, 2019
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung CancerTejas Patil, Rao Mushtaq, Sydney Marsh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2017
Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung CancerTyler P Robin, D Ross Camidge, Kelly Stuhr, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 1, 2021
Mutational Profile Evaluates Response and Survival to First-Line Chemotherapy in Lung CancerYayi He, Lele Song, Hao Wang, et al.
The Lancet. Oncology|March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trialEgbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.
The New England Journal of Medicine|September 17, 2021
Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung CancerBob T Li, Egbert F Smit, Yasushi Goto, et al.
The New England Journal of Medicine|June 3, 2022
Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> MutationPasi A Jänne, Gregory J Riely, Shirish M Gadgeel, et al.
Pageof 3